Condition

Carotid Stenosis (1)

Healthy (1)

Myelofibrosis (1)

Myelofibrosis Transformation in Essential Thrombocythemia (1)

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase (1)

Primary Myelofibrosis (1)

Overall Status

Recruiting (2)

Completed (1)

Withdrawn (1)

Phase

phase 2 (2)

n/a (1)

phase 1 (1)

Sponsor

Galecto Biotech AB (1)

M.D. Anderson Cancer Center (1)

PharmAkea, Inc. (1)

Thomas G. Brott, M.D. (1)

Collaborator

National Cancer Institute (NCI) (1)

National Institute of Neurological Disorders and Stroke (NINDS) (1)

OPIS s.r.l (1)

Study Documents

Intervention Type

drug (3)

other (2)

device (1)

procedure (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

PAT1251

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary

Withdrawn

Myelofibrosis Transformation in Essential Thrombocythemia
+2 more

LOXL2 Inhibitor PAT-1251
+2 more

Houston, Texas

M D Anderson Cancer Center

Aug 9, 2019

Myelofibrosis Trial in Worldwide (GB2064)

Recruiting

Myelofibrosis

GB2064

Houston, Texas
+11 more

Nov 23, 2022

Carotid Stenosis Trial in Worldwide (procedure, device, other)

Recruiting

Carotid Stenosis

Carotid endarterectomy (CEA)
+3 more

Birmingham, Alabama
+159 more

Jan 13, 2023

Healthy Trial in Leeds (PAT-1251, Placebo)

Completed

Healthy

PAT-1251
Placebo

Leeds, United Kingdom

Covance Clinical Research Unit Ltd.

Nov 28, 2016